Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Todagbé Agnandji, Sélidji; Huttner, Angela; E. Zinser, Madeleine; Njuguna, Patricia; Dahlke, Christine; F. Fernandes, José; Yerly, Sabine; Dayer, Julie-Anne; Kraehling, Verena; Kasonta, Rahel; Akim Adégnika, Ayôla; Altfeld, Marcus; Auderset, Floriane; B. Bache, Emmanuel; Biedenkopf, Nadine; Borregaard, Saskia; S. Brosnahan, Jessica; Burrow, Rebekah; Combescure, Christophe; Desmeules, Jules; Eickmann, Markus; K. Fehling, Sarah; Finckh, Axel; Rita Gonçalves, Ana; P. Grobusch, Martin; W. Hooper, Jay; Jambrecina, Alen; L. Kabwende, Anita; Kaya, Gürkan; Kimani, Domtila; Lell, Bertrand; Lemaître, Barbara; W. Lohse, Ansgar; Massinga Loembé, Marguerite; Matthey, Alain; Mordmüller, Benjamin; Nolting, Anne; Ogwang, Caroline; Ramharter, Michael; Schmidt‐Chanasit, Jonas; Schmiedel, Stefan; Silvera, Peter; R. Stahl, Felix; M. Staines, Henry; Strecker, Thomas; Stubbe, Hans; Tsofa, Benjamin; R. Zaki, Sherif; Fast, Patricia; Moorthy, Vasee; Kaiser, Laurent; Krishna, Sanjeev; Becker, Stephan; Kiény, Marie-Paule; Bejon, Philip; G. Kremsner, Peter; M. Addo, Marylyn; Siegrist, Claire‐Anne

doi:10.1056/nejmoa1502924

Public

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Published in New England Journal of Medicine • Apr 2, 2015

Authors:

Sélidji Todagbé Agnandji

Angela Huttner

Madeleine E. Zinser

Abstract

BACKGROUND: The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa. METHODS: We performed three open-label, dose-escalation phase 1...

Subject

Medicine

Immunogenicity

Ebola vaccine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!